ID   BXD_CBDP                Reviewed;        1276 AA.
AC   P19321;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   03-AUG-2022, entry version 179.
DE   RecName: Full=Botulinum neurotoxin type D;
DE            Short=BoNT/D;
DE   AltName: Full=Bontoxilysin-D;
DE   Contains:
DE     RecName: Full=Botulinum neurotoxin D light chain;
DE              Short=LC;
DE              EC=3.4.24.69 {ECO:0000269|PubMed:8175689};
DE   Contains:
DE     RecName: Full=Botulinum neurotoxin D heavy chain;
DE              Short=HC;
DE   Flags: Precursor;
GN   Name=botD;
OS   Clostridium botulinum D phage (Clostridium botulinum D bacteriophage).
OC   Viruses; Duplodnaviria; Heunggongvirae; Uroviricota; Caudoviricetes;
OC   Caudovirales; Siphoviridae.
OX   NCBI_TaxID=29342;
OH   NCBI_TaxID=1491; Clostridium botulinum.
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=BVD/-3 / Type D;
RX   PubMed=2216736; DOI=10.1093/nar/18.18.5556;
RA   Binz T., Kurazono H., Popoff M.R., Eklund M.W., Sakaguchi G., Kozaki S.,
RA   Krieglstein K., Henschen A., Gill D.M., Niemann H.;
RT   "Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin
RT   type D.";
RL   Nucleic Acids Res. 18:5556-5556(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=CB-16 / Type D / phage d-16 phi;
RX   PubMed=1420572; DOI=10.1292/jvms.54.905;
RA   Sunagawa H., Ohyama T., Watanabe T., Inoue K.;
RT   "The complete amino acid sequence of the Clostridium botulinum type D
RT   neurotoxin, deduced by nucleotide sequence analysis of the encoding phage
RT   d-16 phi genome.";
RL   J. Vet. Med. Sci. 54:905-913(1992).
RN   [3]
RP   PARTIAL PROTEIN SEQUENCE, SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN TYPE
RP   D), AND RELEASED AS SINGLE CHAIN.
RC   STRAIN=D-1873 / Type D, and South African / Type D;
RX   PubMed=2668193; DOI=10.1128/iai.57.9.2886-2891.1989;
RA   Moriishi K., Syuto B., Kubo S., Oguma K.;
RT   "Molecular diversity of neurotoxins from Clostridium botulinum type D
RT   strains.";
RL   Infect. Immun. 57:2886-2891(1989).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-21 AND 443-462, RELEASED AS DICHAIN, SUBUNIT, AND
RP   SUBCELLULAR LOCATION.
RC   STRAIN=CB-16 / Type D / phage d-16 phi;
RX   PubMed=8569530; DOI=10.1111/j.1348-0421.1995.tb02229.x;
RA   Ohyama T., Watanabe T., Fujinaga Y., Inoue K., Sunagawa H., Fujii N.,
RA   Oguma K.;
RT   "Characterization of nontoxic-nonhemagglutinin component of the two types
RT   of progenitor toxin (M and L) produced by Clostridium botulinum type D CB-
RT   16.";
RL   Microbiol. Immunol. 39:457-465(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 2-11 AND 443-456,
RP   RELEASED AS SINGLE CHAIN, SUBUNIT, AND SUBCELLULAR LOCATION.
RC   STRAIN=D-4947 / Type D;
RX   PubMed=11713244; DOI=10.1074/jbc.m106762200;
RA   Kouguchi H., Watanabe T., Sagane Y., Sunagawa H., Ohyama T.;
RT   "In vitro reconstitution of the Clostridium botulinum type D progenitor
RT   toxin.";
RL   J. Biol. Chem. 277:2650-2656(2002).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-6, RELEASED AS SINGLE CHAIN, SUBUNIT, AND SUBCELLULAR
RP   LOCATION.
RC   STRAIN=D-4947 / Type D;
RX   PubMed=17581814; DOI=10.1074/jbc.m703446200;
RA   Hasegawa K., Watanabe T., Suzuki T., Yamano A., Oikawa T., Sato Y.,
RA   Kouguchi H., Yoneyama T., Niwa K., Ikeda T., Ohyama T.;
RT   "A novel subunit structure of Clostridium botulinum serotype D toxin
RT   complex with three extended arms.";
RL   J. Biol. Chem. 282:24777-24783(2007).
RN   [7]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE D AND BOTULINUM NEUROTOXIN D LIGHT
RP   CHAIN), IDENTIFICATION OF SUBSTRATE, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION (BOTULINUM NEUROTOXIN D LIGHT CHAIN), AND SUBCELLULAR LOCATION
RP   (BOTULINUM NEUROTOXIN D LIGHT CHAIN).
RC   STRAIN=D-1873 / Type D;
RX   PubMed=8175689; DOI=10.1016/s0021-9258(18)99941-2;
RA   Yamasaki S., Baumeister A., Binz T., Blasi J., Link E., Cornille F.,
RA   Roques B., Fykse E.M., Suedhof T.C., Jahn R., Niemann H.;
RT   "Cleavage of members of the synaptobrevin/VAMP family by types D and F
RT   botulinal neurotoxins and tetanus toxin.";
RL   J. Biol. Chem. 269:12764-12772(1994).
RN   [8]
RP   FUNCTION (BOTULINUM NEUROTOXIN D LIGHT CHAIN), AND CATALYTIC ACTIVITY.
RC   STRAIN=Type D;
RX   PubMed=8197120; DOI=10.1073/pnas.91.11.4688;
RA   Yamasaki S., Hu Y., Binz T., Kalkuhl A., Kurazono H., Tamura T., Jahn R.,
RA   Kandel E., Niemann H.;
RT   "Synaptobrevin/vesicle-associated membrane protein (VAMP) of Aplysia
RT   californica: structure and proteolysis by tetanus toxin and botulinal
RT   neurotoxins type D and F.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:4688-4692(1994).
RN   [9]
RP   SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN D LIGHT CHAIN), RELEASED AS
RP   SINGLE CHAIN, AND BIOTECHNOLOGY.
RC   STRAIN=Type D;
RX   PubMed=15584922; DOI=10.1111/j.1471-4159.2004.02844.x;
RA   Bade S., Rummel A., Reisinger C., Karnath T., Ahnert-Hilger G., Bigalke H.,
RA   Binz T.;
RT   "Botulinum neurotoxin type D enables cytosolic delivery of enzymatically
RT   active cargo proteins to neurones via unfolded translocation
RT   intermediates.";
RL   J. Neurochem. 91:1461-1472(2004).
RN   [10]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE D), RELEASED AS DICHAIN, EUKARYOTIC
RP   TARGET RANGE, SUBUNIT, AND SUBCELLULAR LOCATION.
RC   STRAIN=D-1873 / Type D;
RX   PubMed=16252491; DOI=10.1637/7347-022305r1.1;
RA   Takeda M., Tsukamoto K., Kohda T., Matsui M., Mukamoto M., Kozaki S.;
RT   "Characterization of the neurotoxin produced by isolates associated with
RT   avian botulism.";
RL   Avian Dis. 49:376-381(2005).
RN   [11]
RP   FUNCTION (BOTULINUM NEUROTOXIN D HEAVY CHAIN), POSSIBLE LACK OF
RP   PROTEINACEOUS RECEPTOR, DOMAIN, AND LIPID-BINDING.
RC   STRAIN=D-1873 / Type D;
RX   PubMed=16115873; DOI=10.1074/jbc.m507596200;
RA   Tsukamoto K., Kohda T., Mukamoto M., Takeuchi K., Ihara H., Saito M.,
RA   Kozaki S.;
RT   "Binding of Clostridium botulinum type C and D neurotoxins to ganglioside
RT   and phospholipid. Novel insights into the receptor for clostridial
RT   neurotoxins.";
RL   J. Biol. Chem. 280:35164-35171(2005).
RN   [12]
RP   DISCUSSION OF BELT FUNCTION, AND DOMAIN.
RX   PubMed=17907800; DOI=10.1371/journal.ppat.0030113;
RA   Brunger A.T., Breidenbach M.A., Jin R., Fischer A., Santos J.S., Montal M.;
RT   "Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for
RT   the light chain.";
RL   PLoS Pathog. 3:1191-1194(2007).
RN   [13]
RP   EUKARYOTIC TARGET RANGE.
RX   PubMed=17913314; DOI=10.1016/j.vaccine.2007.08.051;
RA   Steinman A., Galon N., Arazi A., Bar-Giora Y., Shpigel N.Y.;
RT   "Cattle immune response to botulinum type D toxoid: results of a
RT   vaccination study.";
RL   Vaccine 25:7636-7640(2007).
RN   [14]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE D AND BOTULINUM NEUROTOXIN D HEAVY
RP   CHAIN).
RX   PubMed=19650874; DOI=10.1111/j.1471-4159.2009.06298.x;
RA   Rummel A., Haefner K., Mahrhold S., Darashchonak N., Holt M., Jahn R.,
RA   Beermann S., Karnath T., Bigalke H., Binz T.;
RT   "Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding
RT   site prior to stimulation-dependent uptake with botulinum neurotoxin F
RT   utilising the three isoforms of SV2 as second receptor.";
RL   J. Neurochem. 110:1942-1954(2009).
RN   [15]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE D AND BOTULINUM NEUROTOXIN D HEAVY
RP   CHAIN), POSSIBLE PROTEIN RECEPTOR, INTERACTION WITH EUKARYOTIC SV2B, AND
RP   SUBCELLULAR LOCATION.
RC   STRAIN=BVD/-3 / Type D;
RX   PubMed=21483489; DOI=10.1371/journal.ppat.1002008;
RA   Peng L., Tepp W.H., Johnson E.A., Dong M.;
RT   "Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides
RT   as receptors.";
RL   PLoS Pathog. 7:E1002008-E1002008(2011).
RN   [16]
RP   FUNCTION (BOTULINUM NEUROTOXIN D LIGHT CHAIN), SUBSTRATE SPECIFICITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=22289120; DOI=10.1111/j.1348-0421.2012.00434.x;
RA   Yamamoto H., Ida T., Tsutsuki H., Mori M., Matsumoto T., Kohda T.,
RA   Mukamoto M., Goshima N., Kozaki S., Ihara H.;
RT   "Specificity of botulinum protease for human VAMP family proteins.";
RL   Microbiol. Immunol. 56:245-253(2012).
RN   [17]
RP   BIOTECHNOLOGY.
RX   PubMed=24029240; DOI=10.1210/en.2013-1427;
RA   Somm E., Bonnet N., Zizzari P., Tolle V., Toulotte A., Jones R.,
RA   Epelbaum J., Martinez A., Hueppi P.S., Aubert M.L.;
RT   "Comparative inhibition of the GH/IGF-I axis obtained with either the
RT   targeted secretion inhibitor SXN101959 or the somatostatin analog
RT   octreotide in growing male rats.";
RL   Endocrinology 154:4237-4248(2013).
RN   [18]
RP   REVIEW.
RX   PubMed=28356439; DOI=10.1124/pr.116.012658;
RA   Pirazzini M., Rossetto O., Eleopra R., Montecucco C.;
RT   "Botulinum neurotoxins: Biology, pharmacology, and toxicology.";
RL   Pharmacol. Rev. 69:200-235(2017).
RN   [19] {ECO:0007744|PDB:2FPQ}
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 1-436 IN COMPLEX WITH ZINC, AND
RP   COFACTOR.
RC   STRAIN=D-1873 / Type D / phage d-16 phi;
RX   PubMed=16519520; DOI=10.1021/bi052518r;
RA   Arndt J.W., Chai Q., Christian T., Stevens R.C.;
RT   "Structure of botulinum neurotoxin type D light chain at 1.65 A resolution:
RT   repercussions for VAMP-2 substrate specificity.";
RL   Biochemistry 45:3255-3262(2006).
RN   [20] {ECO:0007744|PDB:3N7J}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 862-1276, AND DOMAIN.
RC   STRAIN=D-1873 / Type D / phage d-16 phi;
RX   PubMed=20731382; DOI=10.1021/bi100865f;
RA   Karalewitz A.P., Kroken A.R., Fu Z., Baldwin M.R., Kim J.J., Barbieri J.T.;
RT   "Identification of a unique ganglioside binding loop within botulinum
RT   neurotoxins C and D-SA.";
RL   Biochemistry 49:8117-8126(2010).
RN   [21] {ECO:0007744|PDB:3OBR, ECO:0007744|PDB:3OBT}
RP   X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 863-1276 IN COMPLEX WITH
RP   N-ACETYLNEURAMINIC ACID, FUNCTION (BOTULINUM NEUROTOXIN TYPE D AND
RP   BOTULINUM NEUROTOXIN D HEAVY CHAIN), DOMAIN, GANGLIOSIDE-BINDING, AND
RP   MUTAGENESIS OF LYS-1192; ASP-1233; TYR-1235; TRP-1238; ARG-1239; PHE-1240;
RP   PHE-1242; ASN-1244; TYR-1246; VAL-1251; ASN-1253; LYS-1257 AND SER-1262.
RC   STRAIN=BVD/-3 / Type D;
RX   PubMed=20704566; DOI=10.1042/bj20101042;
RA   Strotmeier J., Lee K., Volker A.K., Mahrhold S., Zong Y., Zeiser J.,
RA   Zhou J., Pich A., Bigalke H., Binz T., Rummel A., Jin R.;
RT   "Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-
RT   binding sites in a ganglioside-dependent manner.";
RL   Biochem. J. 431:207-216(2010).
RN   [22] {ECO:0007744|PDB:3RMX, ECO:0007744|PDB:3RMY}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF MUTATED 862-1276, FUNCTION
RP   (BOTULINUM NEUROTOXIN TYPE D AND BOTULINUM NEUROTOXIN D HEAVY CHAIN),
RP   SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN D HEAVY CHAIN),
RP   GANGLIOSIDE-BINDING, AND MUTAGENESIS OF TRP-1238; ARG-1239 AND PHE-1240.
RC   STRAIN=D-1873 / Type D;
RX   PubMed=21632541; DOI=10.1074/jbc.m111.254086;
RA   Kroken A.R., Karalewitz A.P., Fu Z., Kim J.J., Barbieri J.T.;
RT   "Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into
RT   neurons.";
RL   J. Biol. Chem. 286:26828-26837(2011).
RN   [23] {ECO:0007744|PDB:5BQM, ECO:0007744|PDB:5BQN}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1-896 IN COMPLEX WITH ZINC,
RP   COFACTOR, DOMAIN, BIOTECHNOLOGY, AND DISULFIDE BOND.
RX   PubMed=26324071; DOI=10.1038/srep13397;
RA   Masuyer G., Davies J.R., Moore K., Chaddock J.A., Ravi Acharya K.;
RT   "Structural analysis of Clostridium botulinum neurotoxin type D as a
RT   platform for the development of targeted secretion inhibitors.";
RL   Sci. Rep. 5:13397-13397(2015).
CC   -!- FUNCTION: [Botulinum neurotoxin type D]: Botulinum toxin causes flaccid
CC       paralysis by inhibiting neurotransmitter (acetylcholine) release from
CC       the presynaptic membranes of nerve terminals of the eukaryotic host
CC       skeletal and autonomic nervous system, with frequent heart or
CC       respiratory failure (PubMed:8175689, PubMed:16252491). Precursor of
CC       botulinum neurotoxin D for which a proteinaceous coreceptor is
CC       controversial. In double SV2A/SV2B knockout mice this toxin does not
CC       degrade its synaptobrevin target; introducing SV2A, SV2B or SV2C
CC       restores target cleavage (PubMed:21483489). Recognition of SV2 by this
CC       toxin does not occur via SV2 glycosylation or its large extracellular
CC       loop 4 (PubMed:21483489). Another group does not find a convincing
CC       interaction with SV2 (PubMed:21632541). Thus a protein receptor for
CC       this BoNT serotype has yet to be definitively proven. Recognizes at
CC       least 1 complex polysialylated ganglioside found on neural tissue.
CC       Electrical stimulation increases uptake of toxin in an ex vivo assay,
CC       presumably by transiently exposing a receptor usually found in
CC       eukaryotic target synaptic vesicles (PubMed:19650874, PubMed:21483489,
CC       PubMed:21632541). Upon synaptic vesicle recycling the toxin is taken up
CC       via the endocytic pathway; when the pH of the toxin-containing endosome
CC       drops a structural rearrangement occurs so that the N-terminus of the
CC       heavy chain (HC) forms pores that allows the light chain (LC) to
CC       translocate into the cytosol (By similarity). Once in the cytosol the
CC       disulfide bond linking the 2 subunits is reduced and LC cleaves its
CC       target protein on synaptic vesicles, preventing their fusion with the
CC       cytoplasmic membrane and thus neurotransmitter release (By similarity).
CC       Requires complex eukaryotic host polysialogangliosides for full
CC       neurotoxicity and for binding to neurons (PubMed:20704566,
CC       PubMed:21483489). {ECO:0000250|UniProtKB:P0DPI0,
CC       ECO:0000269|PubMed:16252491, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:20704566, ECO:0000269|PubMed:21483489,
CC       ECO:0000269|PubMed:21632541, ECO:0000269|PubMed:8175689, ECO:0000305}.
CC   -!- FUNCTION: [Botulinum neurotoxin D light chain]: Has proteolytic
CC       activity (PubMed:8175689, PubMed:8197120). After translocation into the
CC       eukaryotic host cytosol, inhibits neurotransmitter release by acting as
CC       a zinc endopeptidase that cleaves the '61-Lys-|-Leu-62' bond of
CC       synaptobrevin-1 (VAMP1), and the equivalent 'Lys-|-Leu' sites in VAMP2
CC       and VAMP3 (PubMed:8175689). Cleaves the '49-Lys-|-Ile-50' bond of
CC       A.californica synaptobrevin (AC P35589) (PubMed:8197120). This chain
CC       probably has to be partially unfolded to translocate into the
CC       eukaryotic host cell cytosol (PubMed:15584922).
CC       {ECO:0000269|PubMed:8175689, ECO:0000269|PubMed:8197120,
CC       ECO:0000305|PubMed:15584922}.
CC   -!- FUNCTION: [Botulinum neurotoxin D heavy chain]: Responsible for host
CC       epithelial cell transcytosis, host nerve cell targeting and
CC       translocation of light chain (LC) into eukaryotic host cell cytosol.
CC       Composed of 3 subdomains; the translocation domain (TD), and N-terminus
CC       and C-terminus of the receptor-binding domain (RBD). The RBD is
CC       responsible for the adherence of the toxin to the eukaryotic target
CC       cell surface. The N-terminus of the TD wraps an extended belt around
CC       the perimeter of the LC, protecting Zn(2+) in the active site; it may
CC       also prevent premature LC dissociation from the translocation channel
CC       and protect toxin prior to translocation (PubMed:17907800). The TD
CC       inserts into synaptic vesicle membrane to allow translocation into the
CC       host cytosol (By similarity). The RBD binds eukaryotic host
CC       phosphatidylethanolamine, which may serve as toxin receptor
CC       (PubMed:16115873). Treatment of synaptosomes with proteinase K does not
CC       reduce HC binding, suggesting there is no protein receptor or it is
CC       protected from extracellular proteases (PubMed:16115873). HC
CC       significantly decreases uptake and toxicity of whole BoNT/D
CC       (PubMed:19650874, PubMed:21483489). HC also interferes with uptake of
CC       tetanus toxin (PubMed:19650874). Has 2 closely located carbohydrate-
CC       binding receptor sites and binds at least 1 GT1b ganglioside
CC       (PubMed:20704566). Bind gangliosides in the order GD2 > GT1b > GD1b
CC       (PubMed:21632541). Interacts with eukaryotic target protein SV2B
CC       (synaptic vesicle glycoprotein 2B) (PubMed:21483489). Expression of
CC       SV2A, SV2B or SV2C in mice knocked-out for the SV2 proteins restores
CC       entry of BoNT/D and cleavage of VAMP2, suggesting SV2 acts as its
CC       receptor (PubMed:21483489). Unlike BoNT/A and BoNT/E, toxin uptake is
CC       not mediated by large extracellular loop 4 of SV2 (PubMed:21483489).
CC       Another group finds very poor interaction with SV2 proteins, suggesting
CC       the possible protein receptor may not have been identified
CC       (PubMed:21632541). {ECO:0000250|UniProtKB:P0DPI0,
CC       ECO:0000269|PubMed:16115873, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:20704566, ECO:0000269|PubMed:21483489,
CC       ECO:0000269|PubMed:21632541, ECO:0000305|PubMed:17907800}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Limited hydrolysis of proteins of the neuroexocytosis
CC         apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on
CC         small molecule substrates.; EC=3.4.24.69;
CC         Evidence={ECO:0000269|PubMed:8175689, ECO:0000269|PubMed:8197120};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:16519520, ECO:0000269|PubMed:26324071};
CC       Note=Binds 1 zinc ion per subunit (PubMed:16519520, PubMed:26324071).
CC       {ECO:0000269|PubMed:16519520, ECO:0000269|PubMed:26324071};
CC   -!- ACTIVITY REGULATION: [Botulinum neurotoxin D light chain]: Inhibited by
CC       dipicolinic acid, captopril, 1,10-phenanthroline and EDTA.
CC       {ECO:0000269|PubMed:8175689}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=28.9 uM for over-expressed human VAMP1
CC         {ECO:0000269|PubMed:22289120};
CC         KM=28 uM for over-expressed human VAMP2
CC         {ECO:0000269|PubMed:22289120};
CC         KM=11.1 uM for over-expressed human VAMP3
CC         {ECO:0000269|PubMed:22289120};
CC         Note=kcat is 0.59, 146.60 and 113.41 sec(-1) for over-expressed human
CC         VAMP1, VAMP2 and VAMP3 respectively. {ECO:0000269|PubMed:22289120};
CC   -!- SUBUNIT: Heterodimer; disulfide-linked heterodimer of a light chain
CC       (LC) and a heavy chain (HC) (PubMed:26324071). The LC has the
CC       proteolytic/pharmacological activity (PubMed:8175689, PubMed:8197120).
CC       The N- and C-termini of the HC mediate channel formation and eukaryotic
CC       host cell binding, respectively. Can also be purified in complex with a
CC       non-toxic component that is larger than the HC (PubMed:16252491).
CC       Single chain toxin from strain D-4947 copurifies with NTHNA, and in
CC       complexes that include NTNHA, HA-70, HA-33 and HA-17 (PubMed:11713244,
CC       PubMed:17581814). Dichain toxin from strain CB-16 phage d-16 phi
CC       copurifies with NTHNA, and in complexes that include NTNHA, HA-55, HA-
CC       33, HA-22 and HA-17 (PubMed:8569530). The stoichiometry of the whole
CC       complex has been modeled as one BoNT/D, one NTNHA, three HA-70, six HA-
CC       33 and three HA-17 (PubMed:17581814). HC interacts with eukaryotic
CC       protein synaptic vesicle glycoprotein 2B (SV2B), which may serve as its
CC       receptor (PubMed:21483489). Another group does not find a convincing
CC       interaction with SV2 (PubMed:21632541). {ECO:0000269|PubMed:11713244,
CC       ECO:0000269|PubMed:16252491, ECO:0000269|PubMed:16519520,
CC       ECO:0000269|PubMed:17581814, ECO:0000269|PubMed:21483489,
CC       ECO:0000269|PubMed:21632541, ECO:0000269|PubMed:8175689,
CC       ECO:0000269|PubMed:8197120, ECO:0000269|PubMed:8569530,
CC       ECO:0000305|PubMed:26324071}.
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin type D]: Secreted
CC       {ECO:0000269|PubMed:11713244, ECO:0000269|PubMed:17581814,
CC       ECO:0000269|PubMed:2668193}.
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin D light chain]: Secreted
CC       {ECO:0000269|PubMed:16252491, ECO:0000269|PubMed:8569530}. Note=In
CC       animals that have ingested BoNT/D LC acts in the eukaryotic host
CC       cytosol (Probable). {ECO:0000305|PubMed:15584922,
CC       ECO:0000305|PubMed:8175689}.
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin D heavy chain]: Secreted
CC       {ECO:0000269|PubMed:16252491, ECO:0000269|PubMed:8569530}. Note=Upon
CC       incubation with hippocampal cell colocalizes with SV2C, probably in
CC       host synaptic vesicles (PubMed:21483489). Upon incubation with primary
CC       neurons HC colocalizes with synaptophysin probably in synaptic vesicles
CC       of presynaptic cells; a small portion also colocalizes with RAB5 and
CC       may be in synaptic vesicle protein sorting endosomes (PubMed:21632541).
CC       Probably integrates into the eukaryotic host synaptic vesicle membrane.
CC       {ECO:0000269|PubMed:21483489, ECO:0000269|PubMed:21632541,
CC       ECO:0000305}.
CC   -!- DOMAIN: [Botulinum neurotoxin D light chain]: Has protease activity
CC       (PubMed:8175689, PubMed:8197120). {ECO:0000269|PubMed:8175689,
CC       ECO:0000269|PubMed:8197120}.
CC   -!- DOMAIN: [Botulinum neurotoxin D heavy chain]: Has 3 functional domains;
CC       the translocation domain (TD) and the receptor-binding domain (RBD)
CC       which is further subdivided into N- and C-terminal domains (N-RBD and
CC       C-RBD, also called Hcn and Hcc) (PubMed:20731382, PubMed:20704566). The
CC       N-terminus of the TD wraps an extended belt around the perimeter of the
CC       LC which occludes the catalytic pocket (PubMed:26324071). The belt
CC       region may be a pseudosubstrate inhibitor which serves as an
CC       intramolecular chaperone for the LC prior to its translocation into the
CC       host cytosol (PubMed:17907800). {ECO:0000269|PubMed:20704566,
CC       ECO:0000269|PubMed:20731382, ECO:0000269|PubMed:26324071,
CC       ECO:0000305|PubMed:17907800}.
CC   -!- BIOTECHNOLOGY: Cargo proteins fused to the N-terminus of whole toxin
CC       are imported into neurons; stabilized cargo proteins are poorer
CC       substrates, suggesting partial unfolding of the cargo protein is
CC       necessary for import (PubMed:15584922). {ECO:0000269|PubMed:15584922}.
CC   -!- BIOTECHNOLOGY: Can be used for targeted secretion inhibition in
CC       eukaryotic cells. A construct with a mammalian growth hormone-releasing
CC       factor ligand domain (GHRH) inserted between the LC and TD, when
CC       injected into rats, leads to decreased growth hormone production. The
CC       GHRH ligand domain binds to the GHRH receptor on somatotrophs where it
CC       is taken up into endosomes. There the TD inserts into the membrane,
CC       releasing LC which cleaves synaptobrevin and inhibits growth hormone
CC       exocytosis (PubMed:24029240, PubMed:26324071).
CC       {ECO:0000269|PubMed:24029240, ECO:0000305|PubMed:26324071}.
CC   -!- MISCELLANEOUS: There are seven antigenically distinct forms of
CC       botulinum neurotoxin: Types A, B, C, D, E, F, and G; new subtypes are
CC       quite frequent. Types C and D can undergo domain swapping to create
CC       hybrid types.
CC   -!- MISCELLANEOUS: Botulism poisoning is usually food-borne, either by
CC       ingesting toxin or bacterial-contaminated food, or less frequently by
CC       inhalation poisoning. In both cases the neurotoxin binds to the apical
CC       surface of epithelial cells in the gut or airway. Toxin undergoes
CC       receptor-mediated endocytosis (using a different receptor than on
CC       target nerve cells), transcytosis across the epithelial cells and
CC       release into the general circulation. Once in the general circulation
CC       it binds to its target cells. {ECO:0000250|UniProtKB:P0DPI0}.
CC   -!- MISCELLANEOUS: Botulinum type D neurotoxin is synthesized by D strains
CC       of C.botulinum which carry the appropriate bacteriophage.
CC       {ECO:0000305|PubMed:1420572, ECO:0000305|PubMed:20731382,
CC       ECO:0000305|PubMed:2216736}.
CC   -!- MISCELLANEOUS: Botulinum type D South African (D-SA) neurotoxin is
CC       released from bacteria as a single chain and presumably cleaved by host
CC       proteases into the active dichain (PubMed:2668193). Botulinum type D-
CC       1873 neurotoxin is released from bacteria as an already-cleaved dichain
CC       (PubMed:16252491). Toxin from strain CB-16 phage d-16 phi is released
CC       as an alread-cleaved dichain (PubMed:8569530). Another toxin (possibly
CC       from phage CE-beta) is released from over-producing E.coli as a single
CC       chain (PubMed:15584922). Type D-4947 is released as a single chain
CC       (PubMed:17581814). {ECO:0000269|PubMed:15584922,
CC       ECO:0000269|PubMed:16252491, ECO:0000269|PubMed:17581814,
CC       ECO:0000269|PubMed:2668193, ECO:0000269|PubMed:8569530}.
CC   -!- MISCELLANEOUS: This protein can also be encoded on a prophage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: BoNT/D causes animal botulism; it is 1,000-fold less
CC       toxic in chickens than BoNT/C1 (PubMed:16252491, PubMed:16115873).
CC       Cattle botulism is often caused by type D (PubMed:17913314).
CC       {ECO:0000269|PubMed:16252491, ECO:0000269|PubMed:17913314,
CC       ECO:0000305|PubMed:16115873}.
CC   -!- SIMILARITY: Belongs to the peptidase M27 family. {ECO:0000305}.
CC   -!- CAUTION: The existence of a proteinaceous coreceptor is unclear. In
CC       double SV2A/SV2B knockout mice this toxin does not degrade its VAMP
CC       target; introducing SV2A, SV2B or SV2C restores target cleavage
CC       (PubMed:21483489). However another group does not find a convincing
CC       interaction with SV2 (PubMed:21632541). {ECO:0000269|PubMed:21483489,
CC       ECO:0000269|PubMed:21632541}.
CC   -!- WEB RESOURCE: Name=BotDB - A Database Resource for Clostridial
CC       Neurotoxins;
CC       URL="https://botdb.abcc.ncifcrf.gov/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X54254; CAA38175.1; -; Genomic_DNA.
DR   EMBL; S49407; AAB24244.1; -; Genomic_DNA.
DR   PIR; S11455; S11455.
DR   PDB; 2FPQ; X-ray; 1.65 A; A=1-436.
DR   PDB; 3N7J; X-ray; 2.00 A; A=862-1276.
DR   PDB; 3OBR; X-ray; 1.72 A; A=863-1276.
DR   PDB; 3OBT; X-ray; 2.00 A; A=863-1276.
DR   PDB; 3OGG; X-ray; 1.65 A; A=863-1276.
DR   PDB; 3RMX; X-ray; 2.75 A; A/B/C/D=862-1276.
DR   PDB; 3RMY; X-ray; 2.30 A; A/B/C/D=862-1276.
DR   PDB; 5BQM; X-ray; 3.10 A; A/C=1-437, B/D=450-861.
DR   PDB; 5BQN; X-ray; 2.30 A; A=1-437, A=450-862.
DR   PDBsum; 2FPQ; -.
DR   PDBsum; 3N7J; -.
DR   PDBsum; 3OBR; -.
DR   PDBsum; 3OBT; -.
DR   PDBsum; 3OGG; -.
DR   PDBsum; 3RMX; -.
DR   PDBsum; 3RMY; -.
DR   PDBsum; 5BQM; -.
DR   PDBsum; 5BQN; -.
DR   SMR; P19321; -.
DR   DrugBank; DB13902; Equine Botulinum Neurotoxin D Immune FAB2.
DR   UniLectin; P19321; -.
DR   ABCD; P19321; 36 sequenced antibodies.
DR   BRENDA; 3.4.24.69; 1462.
DR   Reactome; R-HSA-5250955; Toxicity of botulinum toxin type D (botD).
DR   EvolutionaryTrace; P19321; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:1905576; F:ganglioside GT1b binding; IDA:UniProtKB.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008320; F:protein transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:InterPro.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.1120.10; -; 1.
DR   InterPro; IPR000395; Bot/tetX_LC.
DR   InterPro; IPR036248; Clostridium_toxin_transloc.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011065; Kunitz_inhibitor_STI-like_sf.
DR   InterPro; IPR013104; Toxin_rcpt-bd_C.
DR   InterPro; IPR012928; Toxin_rcpt-bd_N.
DR   InterPro; IPR012500; Toxin_trans.
DR   Pfam; PF01742; Peptidase_M27; 1.
DR   Pfam; PF07951; Toxin_R_bind_C; 1.
DR   Pfam; PF07953; Toxin_R_bind_N; 1.
DR   Pfam; PF07952; Toxin_trans; 1.
DR   PRINTS; PR00760; BONTOXILYSIN.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF50386; SSF50386; 1.
DR   SUPFAM; SSF58091; SSF58091; 1.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Disulfide bond; Hydrolase;
KW   Lipid-binding; Metal-binding; Metalloprotease; Neurotoxin; Protease;
KW   Secreted; Toxin; Virulence; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:11713244,
FT                   ECO:0000269|PubMed:17581814, ECO:0000269|PubMed:8569530"
FT   CHAIN           2..1276
FT                   /note="Botulinum neurotoxin type D"
FT                   /id="PRO_0000444906"
FT   CHAIN           2..442
FT                   /note="Botulinum neurotoxin D light chain"
FT                   /id="PRO_0000029219"
FT   CHAIN           443..1276
FT                   /note="Botulinum neurotoxin D heavy chain"
FT                   /evidence="ECO:0000269|PubMed:8569530,
FT                   ECO:0000305|PubMed:11713244"
FT                   /id="PRO_0000029220"
FT   REGION          443..862
FT                   /note="Translocation domain (TD)"
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0000269|PubMed:20731382"
FT   REGION          458..547
FT                   /note="Belt"
FT                   /evidence="ECO:0000269|PubMed:26324071"
FT   REGION          863..1082
FT                   /note="N-terminus of receptor binding domain (N-RBD), Hcn"
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0000269|PubMed:20731382"
FT   REGION          1083..1276
FT                   /note="C-terminus of receptor binding domain (C-RBD), Hcc"
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0000269|PubMed:20731382"
FT   REGION          1172..1173
FT                   /note="N-acetyl-beta-neuraminic acid"
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0007744|PDB:3OBT"
FT   REGION          1235..1245
FT                   /note="Ganglioside-binding loop"
FT                   /evidence="ECO:0000269|PubMed:21632541"
FT   MOTIF           1252..1255
FT                   /note="Host ganglioside-binding motif"
FT                   /evidence="ECO:0000250|UniProtKB:P0DPI0,
FT                   ECO:0000305|PubMed:20704566"
FT   ACT_SITE        230
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095"
FT   BINDING         229
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:16519520,
FT                   ECO:0000269|PubMed:26324071, ECO:0007744|PDB:2FPQ,
FT                   ECO:0007744|PDB:5BQM"
FT   BINDING         233
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:16519520,
FT                   ECO:0000269|PubMed:26324071, ECO:0007744|PDB:2FPQ,
FT                   ECO:0007744|PDB:5BQM"
FT   BINDING         269
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:16519520,
FT                   ECO:0000269|PubMed:26324071, ECO:0007744|PDB:2FPQ,
FT                   ECO:0007744|PDB:5BQM"
FT   BINDING         1192
FT                   /ligand="N-acetyl-beta-neuraminate"
FT                   /ligand_id="ChEBI:CHEBI:58705"
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0007744|PDB:3OBT"
FT   BINDING         1239
FT                   /ligand="N-acetyl-beta-neuraminate"
FT                   /ligand_id="ChEBI:CHEBI:58705"
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0007744|PDB:3OBT"
FT   DISULFID        437..450
FT                   /note="Interchain (between light and heavy chains)"
FT                   /evidence="ECO:0000305|PubMed:26324071,
FT                   ECO:0007744|PDB:5BQM, ECO:0007744|PDB:5BQN"
FT   VARIANT         15..16
FT                   /note="ND -> PV (in strain: D-SA)"
FT   VARIANT         17..18
FT                   /note="ND -> LQ (in strain: D-1873)"
FT   VARIANT         452
FT                   /note="K -> Q (in strain: D-SA and D-4947)"
FT   VARIANT         457
FT                   /note="R -> F (in strain: D-1873)"
FT   VARIANT         457
FT                   /note="R -> T (in strain: D-SA)"
FT   VARIANT         462
FT                   /note="A -> D (in strain: D-1873)"
FT   VARIANT         489
FT                   /note="K -> N (in strain: CB16)"
FT   VARIANT         644
FT                   /note="N -> K (in strain: CB16)"
FT   VARIANT         1122
FT                   /note="Q -> R (in strain: CB16)"
FT   MUTAGEN         1192
FT                   /note="K->A: Decreased binding of heavy chain (HC) to
FT                   synaptosomes. Significantly decreased HC binding, whole
FT                   toxin is dramatically less neurotoxic; when associated with
FT                   A-1239."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1233
FT                   /note="D->A: Significantly decreased binding of heavy chain
FT                   (HC) to synaptosomes, whole toxin is significantly less
FT                   neurotoxic. Dramatically decreased HC binding, whole toxin
FT                   is dramatically less neurotoxic; when associated with
FT                   A-1239."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1235
FT                   /note="Y->A: Significantly decreased binding of heavy chain
FT                   to synaptosomes, whole toxin is significantly less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1235
FT                   /note="Y->W: Increased binding of heavy chain to
FT                   synaptosomes, whole toxin has half neurotoxicity."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1238
FT                   /note="W->A: Dramatically decreased binding of heavy chain
FT                   (HC) to synaptosomes, whole toxin is dramatically less
FT                   neurotoxic. Loss of HC binding to GD1b, GT1b, GD2 and
FT                   synaptic vesicles, ganglioside-binding loop is disordered
FT                   in crystal."
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0000269|PubMed:21632541"
FT   MUTAGEN         1238
FT                   /note="W->F,Y: Decreased binding of heavy chain to
FT                   synaptosomes, whole toxin is significantly less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1238
FT                   /note="W->L: Significantly decreased binding of heavy chain
FT                   to synaptosomes, whole toxin is dramatically less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1239
FT                   /note="R->A: Significantly decreased binding of heavy chain
FT                   (HC) to synaptosomes, whole toxin is dramatically less
FT                   neurotoxic. Dramatically decreased HC binding, whole toxin
FT                   is dramatically less neurotoxic; when associated with
FT                   A-1192. Significantly decreased HC binding, whole toxin is
FT                   dramatically less neurotoxic; when associated with A-1233.
FT                   Decrease in HC binding to GD1b, GT1b, GD2 and synaptic
FT                   vesicles."
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0000269|PubMed:21632541"
FT   MUTAGEN         1239
FT                   /note="R->Y: Significantly decreased binding of heavy chain
FT                   to synaptosomes, whole toxin is dramatically less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1240
FT                   /note="F->A: Significantly decreased binding of heavy chain
FT                   to synaptosomes, whole toxin is dramatically less
FT                   neurotoxic. Significant decrease in HC binding to GD1b,
FT                   GT1b, GD2 and synaptic vesicles, GBL is well ordered in
FT                   crystal."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1240
FT                   /note="F->W: Increased binding of heavy chain (HC) to
FT                   synaptosomes, whole toxin is slightly less neurotoxic.
FT                   Slightly greater than wild-type HC binding to GT1b."
FT                   /evidence="ECO:0000269|PubMed:20704566,
FT                   ECO:0000269|PubMed:21632541"
FT   MUTAGEN         1242
FT                   /note="F->S: Significantly decreased binding of heavy chain
FT                   to synaptosomes, whole toxin is dramatically less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1242
FT                   /note="F->W: No effect on heavy chain binding to
FT                   synaptosomes, whole toxin is slightly less neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1244
FT                   /note="N->A: Significantly decreased binding of heavy chain
FT                   to synaptosomes, whole toxin is significantly less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1246
FT                   /note="Y->A,S,W: Significantly decreased binding of heavy
FT                   chain to synaptosomes, whole toxin is significantly less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1251
FT                   /note="V->F: Significantly decreased binding of heavy chain
FT                   to synaptosomes, whole toxin is significantly less
FT                   neurotoxic."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1253
FT                   /note="N->A: Significantly decreased binding of heavy chain
FT                   to synaptosomes."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1257
FT                   /note="K->A: Decreased binding of heavy chain to
FT                   synaptosomes."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   MUTAGEN         1262
FT                   /note="S->F: Decreased binding of heavy chain to
FT                   synaptosomes."
FT                   /evidence="ECO:0000269|PubMed:20704566"
FT   STRAND          16..23
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          34..40
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          43..46
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          53..55
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   TURN            67..69
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   TURN            74..77
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           80..97
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           101..112
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          120..122
FT                   /evidence="ECO:0007829|PDB:5BQM"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   TURN            132..134
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          136..142
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          145..152
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          155..159
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           170..172
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           176..178
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           181..183
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          184..186
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          190..193
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   TURN            212..214
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          218..220
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           223..238
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          247..249
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           267..273
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           275..280
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           283..306
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          309..312
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           313..318
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           319..329
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           344..355
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           360..366
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          380..384
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   TURN            390..392
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   TURN            395..397
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   HELIX           403..405
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          408..410
FT                   /evidence="ECO:0007829|PDB:5BQM"
FT   HELIX           411..413
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   TURN            415..417
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   STRAND          421..423
FT                   /evidence="ECO:0007829|PDB:2FPQ"
FT   TURN            426..428
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          433..437
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          451..454
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           455..457
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           470..472
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          533..539
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           542..548
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          559..562
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           564..569
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          573..575
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           579..586
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           594..609
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          620..624
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           628..632
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   TURN            638..641
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           643..650
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           652..655
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           680..682
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           684..711
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           713..744
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   TURN            748..753
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           754..762
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           764..789
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           792..816
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   TURN            817..821
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           828..832
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   TURN            833..836
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   STRAND          844..846
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           847..849
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           850..860
FT                   /evidence="ECO:0007829|PDB:5BQN"
FT   HELIX           864..867
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          868..875
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          878..881
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          883..885
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          888..891
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          896..901
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          904..907
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          909..911
FT                   /evidence="ECO:0007829|PDB:3OBT"
FT   STRAND          914..917
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          931..939
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   HELIX           941..944
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          948..954
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          957..959
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          961..967
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          970..976
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          982..988
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   TURN            991..993
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1003..1009
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1013..1019
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1022..1028
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1040..1044
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1055..1065
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   HELIX           1069..1079
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   TURN            1080..1083
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1090..1092
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1098..1103
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1109..1114
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1117..1122
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1135..1139
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1150..1152
FT                   /evidence="ECO:0007829|PDB:3RMX"
FT   STRAND          1154..1161
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1164..1170
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1188..1196
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   HELIX           1201..1203
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1204..1209
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1218..1222
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1224..1226
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1228..1235
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   TURN            1239..1242
FT                   /evidence="ECO:0007829|PDB:3RMY"
FT   STRAND          1245..1253
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   HELIX           1255..1257
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   HELIX           1261..1263
FT                   /evidence="ECO:0007829|PDB:3OGG"
FT   STRAND          1265..1268
FT                   /evidence="ECO:0007829|PDB:3OGG"
SQ   SEQUENCE   1276 AA;  146872 MW;  C1EC50F46C8233E2 CRC64;
     MTWPVKDFNY SDPVNDNDIL YLRIPQNKLI TTPVKAFMIT QNIWVIPERF SSDTNPSLSK
     PPRPTSKYQS YYDPSYLSTD EQKDTFLKGI IKLFKRINER DIGKKLINYL VVGSPFMGDS
     STPEDTFDFT RHTTNIAVEK FENGSWKVTN IITPSVLIFG PLPNILDYTA SLTLQGQQSN
     PSFEGFGTLS ILKVAPEFLL TFSDVTSNQS SAVLGKSIFC MDPVIALMHE LTHSLHQLYG
     INIPSDKRIR PQVSEGFFSQ DGPNVQFEEL YTFGGLDVEI IPQIERSQLR EKALGHYKDI
     AKRLNNINKT IPSSWISNID KYKKIFSEKY NFDKDNTGNF VVNIDKFNSL YSDLTNVMSE
     VVYSSQYNVK NRTHYFSRHY LPVFANILDD NIYTIRDGFN LTNKGFNIEN SGQNIERNPA
     LQKLSSESVV DLFTKVCLRL TKNSRDDSTC IKVKNNRLPY VADKDSISQE IFENKIITDE
     TNVQNYSDKF SLDESILDGQ VPINPEIVDP LLPNVNMEPL NLPGEEIVFY DDITKYVDYL
     NSYYYLESQK LSNNVENITL TTSVEEALGY SNKIYTFLPS LAEKVNKGVQ AGLFLNWANE
     VVEDFTTNIM KKDTLDKISD VSVIIPYIGP ALNIGNSALR GNFNQAFATA GVAFLLEGFP
     EFTIPALGVF TFYSSIQERE KIIKTIENCL EQRVKRWKDS YQWMVSNWLS RITTQFNHIN
     YQMYDSLSYQ ADAIKAKIDL EYKKYSGSDK ENIKSQVENL KNSLDVKISE AMNNINKFIR
     ECSVTYLFKN MLPKVIDELN KFDLRTKTEL INLIDSHNII LVGEVDRLKA KVNESFENTM
     PFNIFSYTNN SLLKDIINEY FNSINDSKIL SLQNKKNALV DTSGYNAEVR VGDNVQLNTI
     YTNDFKLSSS GDKIIVNLNN NILYSAIYEN SSVSFWIKIS KDLTNSHNEY TIINSIEQNS
     GWKLCIRNGN IEWILQDVNR KYKSLIFDYS ESLSHTGYTN KWFFVTITNN IMGYMKLYIN
     GELKQSQKIE DLDEVKLDKT IVFGIDENID ENQMLWIRDF NIFSKELSNE DINIVYEGQI
     LRNVIKDYWG NPLKFDTEYY IINDNYIDRY IAPESNVLVL VQYPDRSKLY TGNPITIKSV
     SDKNPYSRIL NGDNIILHML YNSRKYMIIR DTDTIYATQG GECSQNCVYA LKLQSNLGNY
     GIGIFSIKNI VSKNKYCSQI FSSFRENTML LADIYKPWRF SFKNAYTPVA VTNYETKLLS
     TSSFWKFISR DPGWVE
//
